Compare NPWR & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPWR | VANI |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.0M | 119.0M |
| IPO Year | 2021 | 2014 |
| Metric | NPWR | VANI |
|---|---|---|
| Price | $1.92 | $1.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $3.50 | $3.50 |
| AVG Volume (30 Days) | ★ 909.8K | 161.4K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $0.92 |
| 52 Week High | $5.20 | $1.92 |
| Indicator | NPWR | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 50.57 |
| Support Level | $1.63 | $1.24 |
| Resistance Level | $2.15 | $1.55 |
| Average True Range (ATR) | 0.16 | 0.08 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 72.73 | 30.13 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. Its business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. The company has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.